DataMEDS AI Stock Soars 253% After $1.5M Helomics Acquisition Enters $40B Cancer Diagnostics Market
DataMEDS AI completed its acquisition of Helomics Corporation, an AI-driven cancer diagnostics laboratory, from Axe Compute for $1.5 million. The deal includes a CLIA/CAP-certified clinical laboratory, precision oncology CRO business, and $1.5 million in cash with zero debt, propelling NASDAQ:MEDS shares up 253% to a new 52-week high of $5.73.